Brought to you by 
Merck licenses NK-1 antagonist VPD737 to Tigercat Pharma
Dec 2013
Executive Summary
Virtual biotech start-up Tigercat Pharma Inc. received exclusive worldwide rights to Merck & Co. Inc.’s Phase II serlopitant (VPD737) for chronic pruritis (itching that lasts for more than six weeks).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Reverse Licensing
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck licenses NK-1 antagonist VPD737 to Tigercat Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice